Please assess the completion status of the following clinical trial:

Trial Title: Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite ALS as defined by revised El Escorial criteria.~2. Age 18 years or older.~3. Symptom onset of weakness or spasticity due to ALS ≤ 60 months prior to Screening Visit.~4. Slow vital capacity (SVC) measure ≥50% of predicted for gender, height, and age at the screening visit.~5. Must be able to swallow capsules throughout the course of the study, according to Site Investigator judgment.~6. Capable of providing informed consent and following trial procedures.~7. For TMS: a resting motor threshold defined as 50% of pulses eliciting a motor evoked potential (MEP) of amplitude ≥ 50 µV.~8. For TTNCS: median Compound Muscle Action Potential (CMAP) ≥ 1.5 mV.~9. Subjects must not have taken riluzole for at least 30 days or be on a stable dose of riluzole for at least 30 days prior to the Screening Visit and continue on the stable dose throughout the course of the study (riluzole-naïve subjects are permitted in the study).~10. Subjects must not have taken medication for muscle cramping such as cyclobenzaprine, baclofen, carisoprodol, or methocarbamol, for at least 30 days prior to screening or be on a stable dose for at least 60 days prior to screening.~11. Geographic accessibility to the site.~12. Women must not become pregnant for the duration of the study and must be willing to use two contraceptive therapies and have a negative pregnancy test throughout the course of the study.~13. Use of medications known to affect the neurophysiology measures in the study must be scheduled, not as needed (pro re nata, PRN). A subject must have been on a fixed dose for 30 days prior to the Screening Visit, and there must be no reason to believe that a subsequent change would be necessary during the course of the study. These medications include: benzodiazepines, muscle relaxants, tricyclic antidepressants, selective serotonin reuptake inhibitors, non-selective serotonin reuptake inhibitors, hypnotics (including anti-histamines) and anti-cholinergics.~Exclusion Criteria:~1. Invasive ventilator dependence, such as tracheostomy.~2. Creatinine level greater than 1.5 mg/dL at screening.~3. Serum Glutamic-Oxaloacetic (SGOT/AST) / Serum Glutamic-Pyruvic (SGPT/ALT) greater than 3 times the upper limit of normal at screening.~4. History of known sensitivity or intolerability to mexiletine or lidocaine.~5. Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia.~6. Clinically significant conduction abnormalities on electrocardiogram or a known history of cardiac arrhythmia.~7. Known history of epilepsy.~8. Known history of congestive heart failure (CHF) or history of myocardial infarction within the past 24 months.~9. Use of mexiletine for 30 days prior to Screening Visit.~10. Exposure to any other experimental agent (off-label use or investigational) including high dose creatine (\>10 grams a day) within 30 days prior to Screening Visit.~11. Metal in the head and neck region, cardiac pacemaker or brain stimulator, cochlear implants, implanted infusion device or personal history of epilepsy.~12. Use of amiodarone, flecainide, duloxetine, tizanidine, or clozapine.~13. Pregnant women or women currently breastfeeding.~14. Placement of Diaphragm Pacing System (DPS) device \< 60 days prior to Screening Visit.~15. Planned DPS device implantation during study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mexiletine, 300 milligrams (Type: ACTIVE_COMPARATOR): Mexiletine, 300 milligrams by mouth per day for 4 weeks.
- Mexiletine, 600 milligrams (Type: ACTIVE_COMPARATOR): Mexiletine, 600 milligrams by mouth per day for 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, by mouth per day for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).